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Introduction
Over the past few decades, the treatment paradigm of 
gastrointestinal (GI) cancers has changed substantially. 
Monoclonal antibodies targeting angiogenesis and the 
epidermal growth factor receptor (EGFR) signaling pathway 
have become standard treatments for advanced colorectal 
cancers (CRCs) (1,2). Small molecule multikinase inhibitors 
have also demonstrated survival benefit in patients with 
refractory CRCs and hepatocellular carcinomas (HCCs) (3,4). 
Most recently, immunotherapy has shown promising clinical 
efficacy in multiple types of GI cancers (5,6). Although 
chemotherapy remains the mainstay of treatments for the 
majority of GI cancers, novel agents either as single agents 
or in combination are being evaluated in clinical trials 
at an accelerated pace. Here we review the major drugs 
that have demonstrated promising therapeutic activity in 
clinical trials. Immunotherapy is not a significant part of the 
discussion here as it is discussed in great detail in another 
review in this issue. 
Growth signaling pathway inhibitors
Inhibition of growth signaling pathways has traditionally 
been a research hot spot for GI cancers, and it has achieved 
significant success with the development and clinical 
use of small molecule kinase inhibitors and monoclonal 
antibodies (1,2,4). Strategies of inhibiting the growth factor 
pathways include targeting cell surface receptors or their 
downstream cellular cascades. Vascular endothelial growth 
factor receptor (VEGFR), MET, c-kit, platelet-derived 
growth factor receptor (PDGFR), and fibroblast growth 
factor receptor (FGFR) are commonly targeted cell surface 
receptors. Activation of these receptors stimulates various 
downstream signaling pathways that promote tumor cell 
proliferation and sustain cell survival. One of the pathways 
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commonly involved is the Raf-MEK-ERK mitogen-
activated protein kinase (MAPK) cascade, in which activated 
Raf kinases phosphorylate the downstream MEK kinases, 
and the latter activate the extracellular signal-regulated 
kinases (ERK), which lead to cell growth (Figure 1) (7). 
Therapeutics targeting the above cell surface receptors 
and the downstream Raf-MEK-ERK pathway have shown 
some promising results in GI cancers in early phase clinical 
studies.
Cabozantinib is a dual inhibitor of the cell surface growth 
receptors VEGFR2 and MET. In a phase II study, patients 
with advanced HCCs were treated with cabozantinib at 
100 mg daily for 12 weeks as the lead-in stage (8). Patients 
who demonstrated partial response (PR) were continued on 
the treatment, whilst those with stable disease (SD) were 
randomized to continue receiving cabozantinib or placebo. 
Among the 41 patients enrolled, half had received prior 
sorafenib. Cabozantinib was frequently associated with 
fatigue, diarrhea, hand-foot syndrome, nausea/vomiting, and 
thrombocytopenia. Sixty percent of patients needed dose 
reductions during the lead-in stage. The overall response 
rate (ORR) was 5%, but 78% of patients had SD. The 
median progression-free survival (PFS) was 4.4 months, 
and the median overall survival (OS) was 15.1 months. 
These results were encouraging given that historically, 
the ORR and the median OS for untreated HCC patients 
Figure 1 Commonly targeted growth factor signaling pathways.
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who received sorafenib were only 2% and 10.7 months, 
respectively (4). A phase III study evaluating cabozantinib 
at a dose of 60 mg daily versus placebo in patients with 
advanced HCC who have received prior sorafenib is 
ongoing (NCT01908426).
Another multikinase inhibitor, regorafenib, targets 
multiple cell surface growth signaling receptors including 
VEGFR1-3, KIT, PDGFR, and FGFR. It has been 
approved for the treatment of advanced CRC. Recent 
data indicated that it is also effective in treating advanced 
HCC. The phase III RESORCE study tested the efficacy 
of regorafenib in patients with HCC who had progressed 
on sorafenib. The results were presented at the European 
Society for Medical Oncology (ESMO) World Congress 
of Gastrointestinal Cancer 2016 (9). A total of 573 patients 
were randomized 2:1 to receive regorafenib at 160 mg 
for 3 weeks every 4-week cycle versus placebo. Severe 
adverse events were experienced in 79.7% of patients 
treated with regorafenib versus 58.5% of those received 
placebo. Common adverse events of regorafenib included 
hypertension, hand-foot syndrome, fatigue, and diarrhea. 
Regorafenib significantly improved the ORR (10.6% vs. 
4.1%; P=0005), PFS (3.1 vs. 1.5 months; HR 0.46; 95% CI: 
0.37–0.56; P<0.001), and OS (10.6 vs. 7.8 months; HR 0.62; 
95% CI: 0.50–0.78; P<0.001) compared to placebo. These 
results are very encouraging and make regorafenib an 
attractive agent for HCC patients progressed on sorafenib. 
Similar to regorafenib, nintedanib is also a multikinase 
inhibitor targeting VEGFR1–3, FGFR, and PDGFR, but 
with a better toxicity profile. In a phase I study, 30 patients 
with previously treated advanced CRC were treated with 
nintedanib (10). This was a heavily pretreated population 
with prior lines of treatment ranging from 1–5. Nintedanib 
was well tolerated with the most common adverse events 
being mild nausea, vomiting, and diarrhea. Only 10% of 
patients had ≥ grade 3 toxicities. Twenty-four patients (80%) 
had SD for ≥8 weeks, and one patient had PR. Compared 
to regorafenib, which provided a SD rate of 40% and a PR 
rate of 1% but caused ≥ grade 3 toxicities in more than 
half of patients (3), nintedanib was much better tolerated 
and seemed to be quite active in refractory CRCs. The 
phase III LUME-Colon 1 trial is comparing nintedanib 
with placebo in patients with previously treated metastatic 
CRC (NCT02149108). This study has finished accrual 
of 764 patients and was estimated to be completed in 
December 2016. 
There has been quite a lot of excitement in targeting 
FGFR, particularly in cholangiocarcinoma. The FGFR 
family consists of four receptors that are activated by 
binding fibroblast growth factors using heparin or heparin 
sulfate proteoglycan as a co-factor (11). Activated FGFR 
triggers complex downstream pathways including the 
phosphoinositide 3-kinase (PI3K)-AKT cascades and the 
Raf-MEK-ERK signaling pathway. FGFR2 fusions have 
been identified in approximately 13% of intrahepatic 
cholangiocarcinomas (12,13). Preliminary efficacy of 
FGFR inhibitors has been demonstrated in patients with 
FGFR2 fusion and preclinical models (14,15). A phase 
II study examined the activity of a pan-FGFR inhibitor, 
BGJ398, in patients with previously treated advanced 
cholangiocarcinoma harboring FGFR2 alterations (16). 
Forty-seven patients received the study drug. FGFR2 
translocations were found in 38 patients, with FGFR2-
BICC1 fusions being the most common (n=9). Nine patients 
had other FGFR alterations, including mutations in FGFR 
and amplifications in FGFR2 and FGFR3. This was a 
heavily pretreated patient population, with 62% of patients 
receiving ≥2 prior lines of therapies, and 11% with ≥4 prior 
regimens. Adverse events were overall manageable, with 
hyperphosphatemia, fatigue, constipation, and diarrhea 
being the most common. Among a total of 36 evaluable 
patients, eight patients (22%) had PR and 19 (53%) had 
SD. Median duration of drug exposure was 188 days. These 
results were encouraging when compared to the median 
PFS of approximately 3 months in patients who received 
second-line therapies for advanced cholangiocarcinoma 
(17,18). Several clinical studies are ongoing to test the role 
of other FGFR inhibitors in cholangiocarcinomas or other 
solid tumors harboring FGFR alterations (NCT02834780, 
NCT01752920). 
Moving from the cell surface receptors to downstream 
signaling cascades, the Raf-MEK-ERK signaling pathway 
is frequently involved in carcinogenesis. The BRAF gene 
encodes an intracellular Raf protein, which upon activation, 
phosphorylates and triggers sequential activation of the 
MEK/ERK protein cascade. BRAF mutations occurred in 
approximately 12% of CRCs (19). Patients with metastatic 
BRAF-mutant CRCs have a worse survival compared to 
their BRAF wild type counterparts, with a median survival 
of approximately one year (20). In contrast to the potent 
activity of the BRAF inhibitor vemurafenib in melanoma, 
single-agent vemurafenib failed in a phase II study of 
patients with metastatic BRAF-mutated CRCs, with an 
ORR of 5% and a median PFS of 2.1 months (21). This 
indicated that the BRAF inhibition alone might not be 
sufficient in treating BRAF-mutant CRCs, and combination 
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therapy might be a better treatment approach. In a phase 
II study, investigators examined the combination of a 
BRAF inhibitor, encorafenib, and the anti-EGFR antibody, 
cetuximab, with or without the PI3Kα inhibitor, alpelisib, 
in patients with previously treated advanced CRCs that 
are BRAF-mutated (22). A total of 102 patients were 
randomized to the triplet versus the doublet arm. Grade 
3–4 adverse events including anemia, hyperglycemia, 
and elevated lipase were more common in the triplet 
arm. The ORR was 27% for the triplet arm versus 22% 
for the doublet arm. Both median PFS (5.4 months for 
triplet versus 4.2 months for doublet; HR 0.8; 95% CI: 
0.5–1.2; P=0.14) and median OS were similar between the 
two arms (13.1 months for triplet versus 12.4 months for 
doublet; HR 1.1; 95% CI: 0.6–2.0). The median OS in this 
study was much better compared to the historical OS of 
approximately 6 months for this patient population (23,24), 
but the survival benefit needs to be confirmed in phase III 
clinical trials. Furthermore, whether the survival benefit 
with additional alpelisib outweighs the increased toxicities 
awaits further examination in future studies. 
Further down the Raf-MEK-ERK pathway, small 
molecule kinase inhibitors targeting the MEK protein, such 
as cobimetinib and trametinib, have prolonged survival in 
patients with BRAF-mutant melanoma (25,26). Ongoing 
efforts are examining the role of MEK inhibitors in CRC. 
A phase Ib study tested the combination of cobimetinib 
with the PD-L1 inhibitor atezolizumab in patients with 
microsatellite stable CRCs. Single agent PD-1 blockade 
does not appear to have significant anti-tumor activity 
in microsatellite stable tumors (5). Inhibiting MEK with 
cobimetinib upregulates the major histocompatibility 
complex (MHC) class I  on tumor cells ,  enhances 
intratumoral T cell filtration, and increases the activity 
of atezolizumab (27). In this study, a total of 23 patients 
received cobimetinib and atezolizumab (28). This was a 
heavily pretreated patient population, with a median of 
three lines of prior therapies. The microsatellite status was 
stable in 30% of patients and unknown in the other 70%. 
There were no dose-limiting toxicities (DLTs) observed 
with the maximum dose of cobimetinib at 60 mg daily. The 
most common adverse events included diarrhea, fatigue, 
rash, pruritus, and nausea. One third of patients experienced 
grade 3 toxicities, with diarrhea being the most common. 
But there were no grade 4 or 5 toxicities. The ORR was 
17%, and the duration of response was not reached (range, 
5.4 to 11.1+ months) by the time results were presented. 
The 6-month PFS and OS rates were 35% and 72%, 
respectively. Again, compared to the historical ORR of 1% 
and median PFS of approximately 2 months in patients 
with refractory CRCs, these results looked extremely 
promising (3). Based on these data, a phase III study 
investigating the activity of cobimetinib plus atezolizumab 
in patients with chemotherapy-refractory advanced CRCs is 
ongoing (NCT02788279). 
Targeting the tumor microenvironment 
The tumor microenvironment is a complex network 
comprised of extracellular matrix (ECM) and a myriad of 
immune cells. It serves as a mechanical and biochemical 
barrier that shields off the delivery and/or attenuates 
the antitumor effect of drugs, and more importantly, 
creates an immunosuppressive environment that impedes 
tumor immune response. Drugs targeting the tumor 
microenvironment have been aimed at different facets of the 
network, including the pro-tumorigenic cytokine signaling 
pathways such as transforming growth factor-β (TGF-β) and 
CC chemokine ligand 2-CC chemokine receptor 2 (CCL2-
CCR2), enzymes or transmembrane proteins that modulate 
T cell activities such as indoleamine-2,3-dioxygenase (IDO) 
and CD40, and the mechanical component of the tumor 
stroma such as hyaluronan (HA). 
The TGF-β cytokine is secreted by tumors and, in 
turn, facilitates tumor progression and invasion. TGF-β 
upregulates VEGF and promotes angiogenesis, suppresses 
the antitumor effect of T cells and natural killer (NK) cells, 
and stimulates the production of metalloproteinases (MMPs) 
that degrade ECM and facilitate tumor invasion (29). The 
TGF-β receptor-1 kinase inhibitor galunisertib was tested 
in a phase II study in patients with advanced HCC who had 
progressed on or were ineligible for sorafenib (30). A total 
of 109 HCC patients with Child Pugh A or B7 disease were 
randomized to receive galunisertib at 160 or 300 mg/day 
on a 2-week on, 2-week off schedule. Twenty-four percent 
of patients had a reduction in serum alpha fetoprotein 
(AFP) levels by >20% from baseline. The median time-to-
progression (TTP) and OS were 2.8 and 8.3 months in the 
overall population, and 4.3 and 21.4 months in the AFP 
responders, respectively. Galunisertib was well tolerated at 
both dose levels. Neutropenia, fatigue, and anemia were the 
most common grade 3–4 adverse events. The 300 mg/day 
dose was found to confer better drug exposure, and it was 
selected for future studies. Another phase II study tested 
galunisertib in patients with advanced HCC but low serum 
AFP levels (31). The majority of patients had received 
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prior sorafenib. Twenty-nine out of 40 patients treated 
with galunisertib had a reduction in serum TGF-β levels 
by >20%. In patients with a TGF-β reduction >20%, the 
median OS was 21.8 months, compared to 7.9 months 
in those without a TGF-β response. Combinations of 
galunisertib and immunotherapy are being evaluated in 
patients with HCC (NCT02423343) and pancreatic cancer 
(NCT02734160). The incorporation of galunisertib into 
neoadjuvant chemoradiotherapy is also being explored 
in locally advanced rectal cancer in a phase II study 
(NCT02688712). 
The CCL2-CCR2 chemokine signaling pathway has been 
avidly studied as a target for anticancer therapies. Tumors 
and stromal cells synthesize the CCL2 ligand, which recruits 
CCR2-positive inflammatory monocytes to the tumors, 
where they can differentiate into immunosuppressive 
tumor-as soc ia ted  macrophages  (TAMs)  (32 ,33) . 
TAMs play an important role in mediating tumor immune 
evasion and promoting tumor progression and invasion 
(34,35). High CCL2 expression and low CD8+ T cell 
infiltrates in the tumors was associated with decreased 
survival in patients who underwent resection of pancreatic 
cancers (36). A phase Ib study tested the combination of 
the CCR2 inhibitor PF-04136309 with FOLFIRINOX 
in patients with borderline resectable or locally advanced 
pancreatic cancers. This combination regimen resulted in 
an ORR of 49% and a disease control rate of 97% (37). PF-
04136309 was generally well tolerated. These results looked 
promising in light of the ORR of 32% and the disease control 
rate of 70% with FOLFIRINOX alone (38). A phase I study 
testing the combination of PF-04136309 with gemcitabine 
and nab-paclitaxel in pancreatic cancer is ongoing 
(NCT02732938). Another CCR2 inhibitor, CCX872-B, 
is being tested in a phase Ib study in combination with 
FOLFIRINOX in patients with advanced pancreatic cancers 
(NCT02345408). 
Apart from the chemokine signaling pathways, T cells 
are also major components of the tumor microenvironment 
and are critical in tumor-specific immune responses. Most 
tumors evade this immune surveillance by a plethora of 
mechanisms, one of which being the IDO pathway. IDO 
is the key enzyme in the catabolism of tryptophan that is 
critical in the differentiation and proliferation of T cells. 
Both tumors and antigen-presenting cells (APCs) express 
IDO, which suppresses tumor-specific cytotoxic T cells 
and enhances the activity of immunosuppressive regulatory 
T cells (39). In a breast cancer mouse model, an IDO 
inhibitor in combination with paclitaxel synergistically 
induced tumor regression (40). A phase I/II study examined 
the combination of an IDO inhibitor, indoximod, with 
gemcitabine and nab-paclitaxel in patients with metastatic 
pancreatic cancer. In this study, five out of 12 patients 
achieved an objective response (42%), including one patient 
with a complete response (41). The combination was well 
tolerated, with common side effects being fatigue, weight 
loss, diarrhea, and peripheral edema. An interim analysis 
of the phase II part of this study continued to confirm 
the efficacy, with 11 out of 30 patients demonstrating an 
objective response (37%) (42). Given that the ORR with 
gemcitabine plus nab-paclitaxel was 23% (43), incorporating 
indoximod into this regimen may provide additional clinical 
benefits. This study remains ongoing to further examine 
the role of indoximod in the treatment of pancreatic cancers 
(NCT02077881).
Another means to activate cytotoxic T cells is via the 
ligation of the transmembrane protein CD40. CD40 is a 
member of the tumor necrosis factor (TNF) superfamily. It 
is widely expressed on APCs and a variety of tumors (44,45). 
Ligation of CD40 on APCs orchestrates the priming and 
activation of tumor-specific cytotoxic T cells and eradicates 
tumors (46,47). CD40 ligation on carcinoma cells also 
upregulates the expression of Fas and TNF in these cells 
and induces apoptosis (48). A phase I study examined the 
combination of an agonist CD40 monoclonal antibody, 
CP-870,893, with gemcitabine in patients with untreated 
advanced pancreatic cancers (49). Four out of 22 patients 
achieved a PR (18%). The combination was generally well-
tolerated, with mild cytokine release syndrome, fatigue, 
and cytopenia being the most common adverse events. 
Phase I studies are ongoing to evaluate several CD40 
agonistic antibodies either alone or in combination with 
immunotherapy in patients with solid tumors. Other 
CD40 antibodies under investigation include APX005M 
(NCT02482168), SEA-CD40 (NCT02376699), and 
RO7009789 (NCT02665416, NCT02304393). 
Besides the signaling pathways that modify immune 
responses, the tumor stroma itself can also be a therapeutic 
target. This is particularly important in pancreatic cancer, 
which is surrounded by a desmoplastic stroma enriched with 
HA. There was some preclinical evidence suggesting that 
HA stimulated pancreatic cancer cell migration (50). High 
expressions of HA in the tumors were associated with shorter 
survival in patients with resected pancreatic cancer (51). 
A PEGylated recombinant human hyaluronidase, 
PEGPH20, depletes HA and was tested in a randomized 
phase II trial (52). In this study, patients with untreated 
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metastatic pancreatic cancers were randomly assigned to 
receive nab-paclitaxel plus gemcitabine with or without 
PEGPH20. A total of 135 patients received at least one 
dose of the study drugs. In all patients, the ORR (with 
vs. without PEGPH20: 41% vs. 34%; P=0.48) and PFS 
(with vs. without PEGPH20: 5.7 vs. 5.2 months; P=0.11) 
were similar. However, in those with high expressions of 
HA, the ORR was better in the PEGPH20 arm (52% vs. 
24%; P=0.038). The PEGPH20 arm also showed a trend 
towards longer PFS (9.2 vs. 4.3 months; HR 0.39; 95% 
CI: 0.15–1.04; P=0.05) and better OS (12 vs. 9 months; 
HR 0.62; 95% CI: 0.26–1.46). The PEGPH20 group 
experienced more thromboembolic events, peripheral 
edema, muscle spasms, and neutropenia, but these toxicities 
were manageable and the incidence of thromboembolic 
events decreased substantially after prophylactic enoxaparin 
was implemented. A phase III study evaluating the efficacy 
of PEGPH20 in combination with nab-paclitaxel and 
gemcitabine in patients with HA-high metastatic pancreatic 
cancers is ongoing (NCT02715804). 
Cancer stemness inhibitor
Cancer stem cells are referred to the subpopulations 
of cancer cells harboring extremely high potential for 
tumorigenesis and have been isolated from various GI 
cancers (53-55). Napabucasin (BBI-608) is a first-in-class 
cancer stemness inhibitor that targets Stat3-dependent 
gene transcription. In a phase Ib study, napabucasin was 
tested in combination with FOLFIRI and bevacizumab in 
patients with advanced CRCs (56). A total of 46 patients 
were enrolled and randomized to receive napabucasin plus 
FOLFIRI with or without bevacizumab. There were no 
DLTs observed in the study, and the most common grade 
3 adverse events were diarrhea and fatigue. An objective 
response was achieved in 13 of the 40 evaluable patients 
(33%). Furthermore, among the 14 evaluable patients who 
were previously refractory to FOLFIRI, three achieved PR 
(25%). These results are intriguing and suggest that a cancer 
stemness inhibitor may re-sensitize refractory patients to 
chemotherapy. A phase III study of napabucasin is ongoing 
in patients with advanced CRCs (NCT02753127).
Other novel targets for GI cancer treatment
IMAB362 is a first-in-class monoclonal antibody against the 
tight junction protein claudin 18.2 (CLDN18.2), which is 
frequently expressed on gastric cancers (57). In the phase 
II FAST trial, patients with CLDN18.2-positive advanced 
gastric or gastroesophageal junction (GEJ) cancers were 
randomized 1:1 to receive epirubicin, oxaliplatin, and 
capecitabine (EOX) with or without IMAB362 (58). A 
total of 161 patients were randomized. IMAB362 plus 
chemotherapy significantly improved the median PFS 
(7.9 vs. 4.8 months; HR 0.47; 95% CI: 0.31–0.70; 1-sided 
P=0.0001) and OS (13.2 vs. 8.4 months; HR 0.51; 95% 
CI: 0.36–0.73; P=0.0001). Moreover, IMAB362 seemed 
to be more beneficial in those who had high expressions of 
CLDN18.2, defined as 2+ or 3+ CLDN18.2 expression in 
≥70% of tumor cells. In these patients, the median OS with 
and without IMAB362 were 16.7 and 9.0 months (HR 0.45; 
P≤0.0005), respectively. Also of note, in this study, patients 
treated with EOX alone only had a median OS of 8.4 months, 
which was inferior to the median OS of 11.2 months with 
EOX in the REAL-2 trial (59). Incorporating IMAB362 
with a better chemotherapy backbone may be worthy of 
investigation in future clinical studies. 
Conclusions
Novel drugs targeting various antitumor mechanisms of GI 
cancers are under rapid development (Table 1). Inhibitors 
targeting growth factor pathways have shown encouraging 
results in early phase studies. By targeting cell surface 
receptors, the multikinase inhibitors cabozantinib and 
regorafenib have demonstrated significant clinical activity 
in advanced HCCs, and both are being tested in phase III 
studies. FGFR inhibitors may alter the treatment paradigm 
of cholangiocarcinoma with FGFR translocations. Agents 
targeting different levels of the cellular Raf-MEK-ERK 
signaling pathway are also being tested in GI cancers. 
In BRAF mutant CRCs, the combination of the BRAF 
inhibitor encorafenib and cetuximab has demonstrated 
promising efficacy and warrants further study in phase III 
trials. The MEK inhibitor cobimetinib seems to enhance 
the antitumor activity of PD-L1 inhibitor in patients 
with microsatellite stable CRCs. Drugs that modify the 
immunosuppressive tumor microenvironment seem to be 
active against GI cancers, but may need to be combined 
with other drugs such as chemotherapy or immunotherapy 
to enhance the antitumor effect. These agents include 
the TGF-β inhibitor galunisertib, CCR2 inhibitors PF-
04136309 and CCX872-B, the IDO inhibitor indoximod, 
the CD40 agonizing antibody CP-870,893, and the 
recombinant hyaluronidase PEGPH20. Last but not least, 
drugs aimed at novel targets are breaking new ground in the 
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treatment of GI cancers. The first-in-class cancer stemness 
inhibitor napabucasin in combination with chemotherapy 
has shown encouraging activity in patients with advanced 
CRCs and may overcome the problem of chemotherapy 
refractoriness in those who are heavily pretreated. In 
addition, the CLDN18.2 inhibitor IMAB362 is active 
against CLDN18.2-positive gastric cancers. Selecting the 
correct patient population and incorporating IMAB362 
with better chemotherapy regimens would be the key for 
future studies.
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